RecruitingNCT07152119
A Study to Learn About Litfulo Capsule in People With Severe Alopecia Areata in Routine Clinical Practice.
Korean Post Marketing Surveillance for Litfulo Capsule
Sponsor
Pfizer
Enrollment
3,000 participants
Start Date
Aug 27, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this observation study is to learn about the safety and effects of the study medicine (called Litfulo) for the potential treatment of Severe Alopecia Areata.
Eligibility
Min Age: 12 Years
Inclusion Criteria1
- Patients with severe alopecia areata who have been determined to start treatment with Litfulo Capsule according to the approved indications of the medicinal product Treatment of severe alopecia areata in adults and adolescents 12 years or older Evidence of a personally signed and dated informed consent document indicating that the patient or their parent(s)/legal guardian, if applicable, have been informed of all pertinent aspects of the study
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGLitfulo
as provided in real world practice.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07152119
Related Trials
A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
NCT0702982841 locations
Study to Evaluate the Safety, Tolerability and How IBI3013 is Taken up and Processed by the Body in Healthy Volunteers After Single-dose Administration, and in Non-segmental Vitiligo Patients and Alopecia Areata Patients After Multiple-dose Administration
NCT075542221 location
A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata
NCT0702971180 locations